Background
The Kinship (or Conflict) Hypothesis [1, 2] suggests that paternally-expressed fetal imprinted genes will tend to increase fetal growth whereas maternally-expressed genes will tend to restrain it. It has been suggested that this is achieved through modifying fetal and placental nutritional demand and supply [3]. This is supported by evidence that polymorphic variation in the fetal genome, particularly in fetal growth genes, could lead to alterations in maternal metabolism in pregnancy [4]. This long-standing hypothesis suggests that imprinted genes mediate the separate reproductive genetic priorities of the mother and the father in pregnancies [1, 2], through their parent-of-origin-mediated expression. Which parentally-transmitted copy of the gene is expressed, and which is repressed, is governed by the particular gene and the tissue in question, as well as the stage of development. We suggested that in altering both maternal metabolism and physiology, variation in the fetal genome could lead to an alteration in maternal glucose concentrations and blood pressures, leading to a change in the risk of individuals developing adverse conditions of pregnancy such as gestational diabetes (GDM) and gestational hypertension [5, 6]. Following up the equivalent results that we found in an H19 knockout mouse model [7], in humans we observed that paternally-transmitted fetal alleles in the IGF2 gene were associated with maternal glucose concentrations in late pregnancy [8] and GDM when contributing towards fetal imprinted gene allele scores [9]. We have also found other fetal imprinted gene variants that are associated with maternal blood pressure in pregnancy [10]. None of the other maternal circulating nutrient groups that could contribute to fetal growth and development appear to have been tested for associations with polymorphic variation in the fetal genome thus far. This includes lipids such as triglycerides.
In addition to the influence of the mother’s dietary intake, concentrations of triglycerides in the maternal circulation during pregnancy appear to be able to be influenced by polymorphic variation in the maternal genome (e.g. [11]). As well as with maternal circulating lipid concentrations, associations with fatty acids in cord blood have been reported for both maternal and fetal polymorphisms (e.g. [12]). Triglycerides in the maternal circulation appear to have a number of positive effects on the pregnancy including being: (a) a mobile energy source, (b) a reservoir of fatty acids in the mother and (c) an important contributor to fetal growth and potentially newborn development (via the de novo biosynthesis of lipids and triglycerides in mammary glands) [13]. However they have also been linked to negative effects of the high abundance of triglycerides in the maternal circulation, e.g. pre-eclampsia, pre-term birth, macrosomia and maternal cardiovascular disease later in life. Triglycerides are strongly associated with fetal growth in women with GDM [14], and changes in their abundance in their circulating concentrations and isoform profile can precede the development of adverse conditions of pregnancy [15]. Whilst acknowledging that there are many factors in pregnancy that may affect the abundance of lipids in the maternal circulation, including variation in the maternal genome, given the potential influence of these triglyceride species on fetal growth and development it seems reasonable to suggest that polymorphic variation in the fetal genome may have its own influence on maternal circulating lipid levels in pregnancy. This could contribute to the regulation of fetal growth and development.
Anzeige
Previously we have found associations between paternally-transmitted fetal IGF2 and late pregnancy maternal glucose concentrations [8, 9]. This led us to the hypothesis that the interaction between the fetal genotype and maternal metabolism occurs early in pregnancy, when GDM is less well defined. We therefore used mass spectrometry-based lipid profiling to identify metabolic signals and test the hypothesis that fetal variants in imprinted genes are associated with the profile of maternal serum lipids during the first half of pregnancy.
Methods
Cohort and sample selection
The prospective and longitudinal Cambridge Baby Growth Study recruited mothers (and their partners and offspring) attending ultrasound clinics during early pregnancy at the Rosie Maternity Hospital, Cambridge, U.K. between 2001 and 2009 [8‐10, 16]. Where possible venous blood (non-fasting) was collected from mothers at recruitment (at the pregnancy booking clinic, around 15 weeks of gestation). After allowing time for clotting, these samples were centrifuged at 3000 g for 10 min. and the serum separated and stored at − 80 °C until they were used. In total, 845 DNA triads were collected from the families of 1074 mothers recruited to the study for whom week 28 75 g oral glucose tolerance test (OGTT) data were collected for GDM studies [8, 9]. Blood and/or mouth swab samples for DNA extraction were collected from the father and the offspring post-partum. In this cohort 96.9% of the offspring were Caucasian, 0.8% were mixed race, 0.6% were Black (African or Caribbean), 0.8% were Oriental and 0.9% were Indo-Asian.
The current analysis was restricted to 767 women for whom we had both DNA family triad samples available and serum samples from around week 15 of pregnancy. To be of use in a range of studies, 200 of these samples (“the Discovery Cohort”) were specifically chosen to have broadly equal: (1) numbers drawn from tertiles of the venous glucose concentration 60 min. post glucose load at the week 28 OGTT, (2) proportions of pregnancies where the baby exhibited “normal”, “catch-up” or “catch-down” growth (defined as > − 0.67 and < + 0.67, > + 0.67, and < − 0.67 respectively, change in weight z-scores over the first year of life) and (3) numbers of the various combinations of compound fetal alleles formed from the paternally-transmitted IGF2 rs1077025 allele [8, 9] and the maternally-transmitted H19 rs2071094 allele [16]. The remaining participants in this analysis (n = 567), were used as an internal Validation Cohort. Clinical characteristics of participants in the Discovery and Validation Cohorts are shown in Table 1. The only detectable difference between the two groups was a slightly shorter mean gestational age at delivery in the Validation Cohort of around 2 days.
Table 1
Characteristics of the study participants drawn from the Cambridge Baby Growth Study
Characteristic | Discovery Cohort (n = 200) | Validation Cohort (n = 567) | p-value |
|---|---|---|---|
Age at delivery (years) | 33.4 (32.8, 34.0) | 33.2 (32.8, 33.6) | 0.6 |
Gestational age at delivery (weeks) | 40.1 (39.9, 40.3) | 39.8 (39.7, 40.0) | 0.02 |
Parity (n) | 1.7 (1.6, 1.8) | 1.7 (1.6, 1.8) | 0.6 |
Pre-pregnancy BMI (kg/m2) | 23.9 (23.2, 24.6) | 24.2 (23.8, 24.6) | 0.5 |
Weight gain during pregnancy (kg) | 9.2 (8.0, 10.4) | 9.0 (8.2, 9.7) | 0.8 |
Week 28 OGTT fasting glucose concentration (mmol/L) | 4.3 (4.2, 4.4) | 4.3 (4.3, 4.3) | 0.9 |
Week 28 OGTT 60 min. glucose concentration (mmol/L) | 6.4 (6.2, 6.7) | 6.6 (6.5, 6.8) | 0.1 |
Week 28 fasting insulin concentration (pmol/L) | 44.9 (41.7, 48.4) | 45.6 (43.7, 47.6) | 0.7 |
Week 28 fasting insulin resistance (HOMA IR) | 0.915 (0.850, 0.985) | 0.925 (0.886, 0.965) | 0.8 |
Carrying a male fetus (%) | 49.2 | 52.6 | 0.4 |
Smoking during pregnancy (%) | 2.6 | 4.9 | 0.2 |
Gene selection and genetics
Genomic DNA was extracted from blood samples or mouth swabs using an Autopure LS Machine (Qiagen Ltd., Crawley, U.K.). The 16 genes that were studied (DLK1, FAM99A, GNAS, GRB10, H19, IGF2, INS, KCNQ1OT1, MEST, NNAT, PEG3, PEG10, PLAGL1, SGCE, SNRPN, ZIM2) were chosen because they were all imprinted at some stage of development in certain tissues. They were also all placentally-expressed [17], although by the time in pregnancy that the placenta was fully functional some of them may have been biallelically expressed. The variants that were genotyped were haplotype tag SNPs covering the gene and 20 kb either side of it, identified by Tagger (r2 > 0.8 and minor allele frequency > 0.2) from the Centre d’Etude du Polymorphisme Human population (Utah residents with ancestry from Northern and Western Europe) of HapMap Project Build 36 using Haploview [18]. The one exception to this was IGF2 where 11 of the tagging SNPs were identified by Rodríguez et al. [19]. The SNPs that were genotyped are listed in Table 2. The DNA samples were genotyped using KASPar assays, which are competitive allele-specific PCR SNP genotyping assays using FRET quencher cassette oligonucleotides (designed and performed by LGC Genomics, Hoddesdon, U.K.). The SNP genotypes that were used in this study were consistent with Hardy Weinberg equilibrium (p > 0.05 using the χ2 test) and had a repeat genotyping discordancy rate of < 1.0%. For each of the 151 SNPs that were successfully designated, genotypes from both parents and their child were used to infer parental allelic transmission to the fetus according to Table 3.
Table 2
The SNPs that were genotyped for this study
Gene | No. of SNPs | Single nucleotide polymorphisms |
|---|---|---|
DLK1
| 5 | rs12147008, rs7155375, rs10139403, rs1802710, rs7147586 |
FAM99A*
| 7 | rs4752779, rs4752781, rs11600502, rs10839220, rs11607954, rs1489945, rs7131362 |
GNAS
| 20 | rs6123832, rs965808, rs6128441, rs6026561, rs6026560, rs12625436, rs4810148, rs7271854, rs6100260, rs6026576, rs6128461, rs6123837, rs13831, rs234630, rs919196, rs3730168, rs919197, rs7121, rs234623, rs234621 |
GRB10
| 17 | rs4245555, rs12669770, rs7802879, rs7777754, rs2715129, rs3807549, rs2299150, rs11769934, rs2237441, rs1468450, rs6948959, rs980716, rs2715116, rs737292, rs7794604, rs17133917, rs2237450 |
H19
| 13 | rs2071094, rs2735466, rs7950932, rs217222, rs217727, rs2251375, rs217228, rs3741216, rs1706879, rs2735971, rs7950715, rs7950787, rs12417375 |
IGF2*
| 17 | rs6578987, *rs734351, *rs4341514, rs680, *rs3741212, *rs11603378, *rs3213216, *rs10770125, *rs3741205, *rs3741206, rs1004446, *rs4320932, *rs3842752, *rs7924316, *rs7483056, *rs6356, *rs10743152 |
INS*
| 16 | *rs734351, *rs4341514, rs2585, *rs3741212, *rs11603378, *rs3213216, *rs10770125, *rs3741205, *rs3741206, *rs4320932, rs3741211, *rs3842752, *rs7924316, *rs7483056, *rs6356, *rs10743152 |
KCNQ1OT1*
| 14 | rs231352, rs463924, rs4930005, rs231841, rs10832514, rs756852, rs7128926, rs10832430, rs231361, rs760419, rs9666537, rs7929804, rs10766218, rs6578283 |
MEST
| 6 | rs12706933, rs13234660, rs765205, rs13225903, rs1047456, rs10954272 |
NNAT
| 3 | rs6066671, rs12481150, rs6019103 |
PEG3*
| 8 | rs17207579, rs11084466, *rs2079877, *rs7256072, *rs382592, rs758752, rs7248098, *rs1860565 |
PEG10
| 5 | rs1568214, rs13073, rs1533831, rs6948099, rs6465422 |
PLAGL1
| 20 | rs12528289, rs9484833, rs1884087, rs10499846, rs2268440, rs6930726, rs7770529, rs2268443, rs2876578, rs9373409, rs2268445, rs17073273, rs9403542, rs9484836, rs6570599, rs2328537, rs9321957, rs6937128, rs9767615, rs2207851 |
SGCE
| 2 | rs1879854, rs7778237 |
SNRPN
| 12 | rs7164801, rs17114774, rs7171320, rs1453556, rs4028398, rs1982981, rs736008, rs9806682, rs7164989, rs8042562, rs12592279, rs8029318 |
ZIM2*
| 8 | *rs2079877, rs12981689, rs1476830, *rs7256072, *rs382592, *rs1860565, rs2286751, rs10401139 |
Table 3
Imputation table of parentally transmitted fetal alleles based on family triad genotypes
Paternal Genotype | Maternal Genotype | Fetal Genotype | Paternally-transmitted Allele | Maternally-transmitted Allele |
|---|---|---|---|---|
A/A | A/A | A/A | A | A |
A/A | A/a | A/A | A | A |
A/A | A/a | A/a | A | a |
A/A | a/a | A/a | A | a |
A/a | A/A | A/A | A | A |
A/a | A/A | A/a | a | A |
A/a | A/a | A/A | A | A |
A/a | A/a | A/a | Uninformative | Uninformative |
A/a | A/a | a/a | a | a |
A/a | a/a | A/a | A | a |
A/a | a/a | a/a | a | a |
a/a | A/A | A/a | a | A |
a/a | A/a | A/a | a | A |
a/a | A/a | a/a | a | a |
a/a | a/a | a/a | a | a |
Anzeige
Lipid profiling: Sample extraction and mass spectrometry
The lipid profiles of maternal serum from the Discovery Cohort were analysed using the direct infusion mass spectrometry method that we developed for use with dried blood spots [20, 21], which was originally based on a method for plasma [22]. All solvents were of at least liquid chromatography–mass spectrometry (LC–MS) grade and were purchased from Sigma Aldrich (Gillingham, Dorset, U.K.). All internal standards were obtained from Avanti Polar lipids (through Instruchem, Delfzijn, The Netherlands) except for undecanoic acid and trilaurin (Sigma Aldrich).
Samples were subjected to a balanced randomisation to achieve an approximately equal number of genotypes in each batch (2 × 68 samples and 1 × 64 samples). A serum pool was created by using 5 μL of a random subset of samples, to create the first quality control (QC1). Part of the pooled sample was diluted with phosphate buffered saline (PBS), either mixing the pooled sample 1:1 with PBS (to create QC2) or 1:4 with PBS (to create QC3). From the QC material 15 μL was aliquoted into 1.2 mL Cryovials and stored at − 80 °C prior to use. Quality assurance (QA) samples used were based on commercially available human plasma. Each batch had 6 x blanks, 6 x QAs, 4 x QC1, 4 x QC2, 4 xQC3. The extraction method for the lipids used a Flexus automated liquid handler (Anachem, Milton Keynes, UK) for pipetting. 15 μL serum samples were extracted using tert-butyl methyl ether (MTBE), containing the following internal standards: 1,2-di-O-octadecyl-glycero-sn-3-phosphatidylcholine, 1,2-di-O-phytanyl-glycero-sn-3-phosphatidylethanolamine, C8-ceramide, N-heptadecanoyl-D-erythro-sphingosylphosporylcholine, undecanoic acid and trilaurin on glass coated 2.4 mL deep well plates (Plate+TM, Esslab, Hadleigh, UK) as described [20]. A 96 head micro-dispenser (Hydra Matrix, Thermo Fisher Ltd., Hemel Hampstead, U.K.) was used to transfer 25 μL of the lipid extract to a glass coated low well plate (Plate+TM, Esslab, Hadleigh, U.K.) and with 90 μL of MS-mix (7.5 mM NH4Ac IPA:MeOH (2:1)) using a Hydra Matrix, after which the plate was sealed using Corning aluminium microplate sealing tape (Sigma-Aldrich Company, U.K.) and stored at − 20 °C until analysis.
At 15 °C throughout, 5 μL of sample was dispensed into the mass spectrometer (Thermo Fisher Exactive benchtop orbitrap; Hemel Hempstead, U.K.) using an Advion Triversa Nanomate (Ithaca, New York, U.S.A.) electrospray ioniser under 0.2 psi nitrogen pressure. Ionisation was achieved with a potential of 1.2 kV. Data acquisition started 20 s. after sample aspiration began. After 72 s. of acquisition in positive mode, negative mode was adopted by changing the potential to − 1.5 kV. The spray was maintained for another 66 s.
Liquid chromatography–mass spectrometry
Lipids were identified using a selected subset of samples analysed using a LTQ Orbitrap Velos Elite coupled to a Surveyor (both Thermo Fisher, Hemel Hampstead, U.K.) LC system as described [21]. The Orbitrap was set-up using the data-dependent precursor selection. Generally the selected masses were isolated with a 1.5 m/z width in the linear ion trap and then fragmented using either linear ion trap with 35% relative collision energy or in the higher-energy collision-induced dissociation collision cell, with a range from 5 to 75% relative collision energy. All spectra were recorded in the Orbitrap set at 100,000 resolution. All species recorded were identified based on accurate mass and subsequently based on accurate mass MS2 spectra and retention time from the LC–MS experiment.
The maternal serum lipid profiles of the Validation Cohort were subsequently analysed by LC–MS rather than by the direct infusion mass spectrometry that was used for the Discovery Cohort [23], using the method described previously [24].
The raw mass spectrometry data were converted to .mzXML format using MS Convert, parsed to R and 50 spectra averaged per mode using XCMS (http://bioconductor.org/packages/release/bioc/html/xcms.html). Additional processing was then conducted using an in-house R script (Peakpicker version 2.0) to select peaks, deisotope and annotate direct-infusion mass spectrometry data sets. Only those lipid species where more than 70% (140) of the samples contained detectable concentrations and showed a linear correlations with diluted QC range were used. Accordingly 173 lipid/triglyceride species were considered for statistical analysis.
Other assays and calculations
Blood glucose concentrations were measured using a routine glucose oxidase-based method. Maternal plasma insulin concentrations were measured using a DSL ELISA (London, U.K.) run according to the manufacturer’s instructions. Homeostatic model assessment of insulin resistance (HOMA IR) was estimated using the HOMA calculator [25]. Body mass index (BMI) was calculated as the body weight (kg) divided by the height (m) squared.
Statistical power
In the Discovery Cohort there was 80% statistical power to detect a difference of 1.37 standard deviations in lipid species concentrations for a variant with a minor allele frequency of 0.4 (α = 0.05). The equivalent value for the Validation Cohort was 1.21. There was 80% statistical power in the random-effects meta-analysis with moderate heterogeneity for a small effect size (Cohen’s d) of 0.29 (α = 0.05).
Anzeige
Statistical analyses
Lipid profiles in the Discovery Cohort were analysed by Partial Least Squares – Discriminant Analysis (PLS-DA), a multivariate dimensionality-reduction tool with awareness of class labels, using Metaboanalyst 3.0 [26]. The peak intensity table from the mass spectrometry was loaded into the software and the default data integrity check accepted. Without data filtering, the log-transformed data was normalised using the median and scaled using mean centring. Fitted models were considered significant if the value of Q2 (representing the predictive capability of the model, as estimated by cross-validation) was positive [23]. The importance of individual lipid species was quantified via the variable importance in projection (VIP) score, a weighted sum of squares of the PLS-DA loadings that takes into account the amount of explained lipid profile variance for each component, and used to identify individual candidate lipid species (with a threshold VIP score of greater than 2.0 in this study) that may be significantly associated with fetal imprinted gene alleles. These associations (and those with maternal genotypes) were then tested using linear regression models in both the Discovery and Validation Cohorts. Analysis of the associations in the full cohort was by meta-analysis rather than combining results from both sub-Cohorts into one because of the different laboratory methods used to assess the lipid profiles. The meta-analysis was analysed using the Der Simonian-Laird approach [27] for random effects models implemented into the R Metacor package, version 1.0–2 (https://cran.r-project.org/packages/metacor/index.html). Additional analyses were then performed to assess potential imprinting effects on the associations, by testing associations between the lipid species and the maternal genotypes, the maternal untransmitted allele and the fetal imprinted allele transmitted from the parent whose allele did not produce significant fitted models in Metaboanalyst.
Categorical and ordinal data were analysed using the χ2 or Fisher’s exact tests, or logistic regression. Associations with p < 0.05 were considered significant throughout. Apart from the use of Metaboanalyst, and the meta-analyses which were performed in R (version 3.2.2; https://cran.r-project.org/bin/windows/base/), all other statistical analyses were performed in Stata (version 13.1; StataCorp LP, College Station, TX, U.S.A.).
Results
Associations between fetal imprinted gene alleles and the maternal lipid profile around week 15 of pregnancy
The associations between the peak intensities of individual lipid species (that produced significant fitted models in the PLS-DA analysis of the Discovery Cohort) and fetal imprinted gene alleles are shown in Table 4. The most significant fetal imprinted gene allele associations both related to TG(44:1), namely paternally-transmitted H19 rs7950932 and maternally-transmitted FAM99A rs7131362. Of the associations in this list, not all of which reached statistical significance, there was a predominance of associations of species with maternally-expressed fetal alleles in the Discovery Cohort analyses (p = 0.01). Due to this we also tested associations between the same species and both the maternal genotype (Table 5) and the untransmitted maternal allele (Table 6) to investigate whether the associations were most likely fetally- or maternally-mediated. All other associations were considered non-significant (data not shown). To assess whether the associations highlighted in Table 4 were parent-of-origin effects we also tested associations between the same species and fetal alleles transmitted from the parent whose allele did not produce significant fitted models in the PLS-DA analysis of the Discovery Cohort (Table 7). Fetal H19 rs7950932 alleles transmitted from both parents showed significant associations with maternal TG(44:1) peak intensity (Tables 4 and 7), and we also found significant associations with the fetal rs7950932 genotype (Discovery Cohort R = 0.17, p = 0.01, n = 191; Validation cohort R = 0.10, p = 0.08, n = 220; meta-analysis R = 0.13 (0.04–0.23), p = 3.6 × 10− 3).
Table 4
Associations between fetal genotypes and candidate lipid species’ peak intensity
SNP | Gene | Parental Transmission | Lipid | VIP Score of lipid species* | Discovery Cohort | Validation Cohort | Meta-Analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
R | p-value | n | R | p-value | n | R | p-value | |||||
rs10839220 |
KRTAP5–6
| Maternal | TG(44:1) | 3.4 | 0.175 | 0.03 | 163 | 0 | 0.96 | 197 | 0.09 (− 0.09, 0.25) | 0.17 |
rs10839220 |
KRTAP5–6
| Maternal | LysoPCP(18:0) | 2.8 | 0.243 | 1.8 × 10− 3 | 163 | 0.092 | 0.16 | 233 | 0.16 (0.01, 0.31) | 0.02 |
rs10839220 |
KRTAP5–6
| Maternal | PE(34:0) | 2.2 | 0.279 | 3.2 × 10−4 | 163 | 0.014 | 0.85 | 233 | 0.15 (−0.12, 0.39) | 0.14 |
rs10839220 |
KRTAP5–6
| Maternal | DG(36:3) | 2.1 | 0.271 | 4.6 × 10−4 | 163 | 0.118 | 0.09 | 209 | 0.19 (0.04, 0.34) | 7.4 × 10−3 |
rs4752779 |
FAM99B
| Maternal | TG(44:1) | 3.2 | 0.161 | 0.03 | 173 | 0.030 | 0.67 | 201 | 0.09 (−0.04, 0.22) | 0.08 |
rs7131362 |
FAM99A
| Maternal | TG(44:1) | 4.7 | 0.257 | 9.7 × 10−4 | 161 | 0.114 | 0.12 | 190 | 0.18 (0.04, 0.32) | 6.2 × 10−3 |
rs7131362 |
FAM99A
| Maternal | TG(48:0) | 2.1 | 0.197 | 0.01 | 161 | 0 | 0.95 | 217 | 0.10 (−0.10, 0.28) | 0.17 |
rs17073273 |
PLAGL1
| Maternal | TG(44:1) | 3.5 | 0.181 | 0.02 | 175 | 0.014 | 0.83 | 206 | 0.09 (−0.07, 0.25) | 0.13 |
rs17073273 |
PLAGL1
| Maternal | TG(55:9) | 2.7 | 0.234 | 1.8 × 10−3 | 175 | 0.079 | 0.23 | 235 | 0.15 (0.00, 0.30) | 0.03 |
rs17073273 |
PLAGL1
| Maternal | TG(48:0) | 2.5 | 0.226 | 2.6 × 10−3 | 175 | 0.035 | 0.59 | 235 | 0.13 (−0.06, 0.31) | 0.09 |
rs2268445 |
PLAGL1
| Maternal | TG(44:1) | 3.6 | 0.189 | 0.01 | 176 | 0.035 | 0.62 | 212 | 0.11 (−0.04, 0.26) | 0.08 |
rs7950932 |
H19
| Paternal | TG(44:1) | 2.6 | 0.167 | 0.02 | 183 | 0.117 | 0.10 | 203 | 0.14 (0.04, 0.24) | 2.3 × 10−3 |
Table 5
Associations between maternal imprinted gene SNP genotypes and candidate lipid species’ peak intensity
SNP | Gene | Lipid | Discovery Cohort | Validation Cohort | Meta-Analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|
R | p-value | n | R | p-value | n | R | p-value | |||
rs10839220 |
KRTAP5–6
| TG(44:1) | 0.157 | 0.04 | 179 | 0.017 | 0.78 | 225 | 0.08 (−0.05, 0.22) | 0.12 |
rs10839220 |
KRTAP5–6
| LysoPCP(18:0) | 0.205 | 5.8 × 10−3 | 179 | 0 | 0.92 | 267 | 0.10 (−0.10, 0.29) | 0.17 |
rs10839220 |
KRTAP5–6
| PE(34:0) | 0.194 | 9.2 × 10−3 | 179 | 0.051 | 0.41 | 267 | 0.12 (− 0.02, 0.25) | 0.05 |
rs10839220 |
KRTAP5–6
| DG(36:3) | 0.224 | 2.6 × 10−3 | 179 | 0.062 | 0.34 | 240 | 0.14 (−0.02, 0.29) | 0.04 |
rs4752779 |
FAM99B
| TG(44:1) | 0.102 | 0.17 | 180 | 0.045 | 0.51 | 227 | 0.07 (−0.03, 0.17) | 0.08 |
rs7131362 |
FAM99A
| TG(44:1) | 0.222 | 2.9 × 10− 3 | 178 | 0.041 | 0.54 | 221 | 0.13 (−0.05, 0.30) | 0.08 |
rs7131362 |
FAM99A
| TG(48:0) | 0.150 | 0.05 | 178 | 0.030 | 0.64 | 251 | 0.08 (−0.03, 0.20) | 0.08 |
rs17073273 |
PLAGL1
| TG(44:1) | 0.042 | 0.56 | 188 | 0.033 | 0.61 | 234 | 0.04 (−0.06, 0.13) | 0.23 |
rs17073273 |
PLAGL1
| TG(55:9) | 0.125 | 0.09 | 188 | 0.117 | 0.06 | 267 | 0.12 (0.03, 0.21) | 5.2 × 10−3 |
rs17073273 |
PLAGL1
| TG(48:0) | 0.084 | 0.25 | 188 | 0.057 | 0.35 | 267 | 0.07 (− 0.02, 0.16) | 0.07 |
rs2268445 |
PLAGL1
| TG(44:1) | 0.046 | 0.54 | 187 | 0.071 | 0.28 | 231 | 0.06 (−0.04, 0.16) | 0.11 |
Table 6
Associations between maternal untransmitted alleles and candidate lipid species’ peak intensity
SNP | Gene | Lipid | Discovery Cohort | Validation Cohort | Meta-Analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|
R | p-value | n | R | p-value | n | R | p-value | |||
rs10839220 |
KRTAP5–6
| TG(44:1) | 0.113 | 0.16 | 154 | 0.067 | 0.38 | 179 | 0.09 (−0.02, 0.19) | 0.05 |
rs10839220 |
KRTAP5–6
| LysoPCP(18:0) | 0.095 | 0.24 | 154 | 0.114 | 0.10 | 213 | 0.11 (0, 0.21) | 0.02 |
rs10839220 |
KRTAP5–6
| PE(34:0) | 0.068 | 0.54 | 154 | 0.042 | 0.40 | 213 | 0.05 (−0.05, 0.15) | 0.16 |
rs10839220 |
KRTAP5–6
| DG(36:3) | 0.122 | 0.13 | 154 | 0 | 0.98 | 190 | 0.06 (−0.06, 0.17) | 0.18 |
rs4752779 |
FAM99B
| TG(44:1) | 0.020 | 0.81 | 161 | 0.054 | 0.47 | 185 | 0.04 (−0.07, 0.14) | 0.24 |
rs7131362 |
FAM99A
| TG(44:1) | 0.119 | 0.14 | 153 | 0.050 | 0.51 | 175 | 0.08 (−0.03, 0.19) | 0.07 |
rs7131362 |
FAM99A
| TG(48:0) | 0.080 | 0.43 | 153 | 0.065 | 0.26 | 198 | 0.07 (−0.03, 0.18) | 0.09 |
rs17073273 |
PLAGL1
| TG(44:1) | 0.131 | 0.09 | 170 | 0.024 | 0.74 | 201 | 0.07 (−0.03, 0.18) | 0.09 |
rs17073273 |
PLAGL1
| TG(55:9) | 0 | 0.98 | 170 | 0.123 | 0.06 | 228 | 0.07 (−0.05, 0.19) | 0.13 |
rs17073273 |
PLAGL1
| TG(48:0) | 0.094 | 0.22 | 170 | 0.067 | 0.31 | 228 | 0.08 (−0.02, 0.18) | 0.06 |
rs2268445 |
PLAGL1
| TG(44:1) | 0.092 | 0.23 | 172 | 0.022 | 0.76 | 201 | 0.05 (−0.05, 0.16) | 0.15 |
Table 7
Associations between candidate lipid species’ peak intensity and alleles transmitted from the other parent than those with significant fitted models
SNP | Gene | Parental Transmission | Lipid | Discovery Cohort | Validation Cohort | Meta-Analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
R | p-value | n | R | p-value | n | R | p-value | ||||
rs10839220 |
KRTAP5–6
| Paternal | TG(44:1) | 0.12 | 0.14 | 161 | 0.08 | 0.26 | 200 | 0.10 (−0.01, 0.20) | 0.03 |
rs10839220 |
KRTAP5–6
| Paternal | LysoPCP(18:0) | 0.07 | 0.40 | 161 | 0.12 | 0.07 | 235 | 0.07 (−0.03, 0.17) | 0.08 |
rs10839220 |
KRTAP5–6
| Paternal | PE(34:0) | 0.10 | 0.20 | 161 | 0.11 | 0.10 | 235 | 0.11 (0.01, 0.20) | 0.02 |
rs10839220 |
KRTAP5–6
| Paternal | DG(36:3) | 0.05 | 0.53 | 161 | 0.18 | 8.4 × 10−3 | 213 | 0.12 (−0.01, 0.25) | 0.03 |
rs4752779 |
FAM99B
| Paternal | TG(44:1) | 0.03 | 0.66 | 174 | 0.04 | 0.61 | 205 | 0.04 (−0.07, 0.14) | 0.25 |
rs7131362 |
FAM99A
| Paternal | TG(44:1) | 0.05 | 0.57 | 159 | 0.01 | 0.86 | 204 | 0.03 (−0.08, 0.13) | 0.30 |
rs7131362 |
FAM99A
| Paternal | TG(48:0) | 0.03 | 0.68 | 159 | 0.03 | 0.64 | 232 | 0.03 (−0.07, 0.13) | 0.26 |
rs17073273 |
PLAGL1
| Paternal | TG(44:1) | 0.14 | 0.07 | 174 | 0.08 | 0.26 | 216 | 0.11 (0.01, 0.20) | 0.02 |
rs17073273 |
PLAGL1
| Paternal | TG(55:9) | 0.13 | 0.08 | 174 | 0.03 | 0.66 | 248 | 0.07 (−0.03, 0.17) | 0.08 |
rs17073273 |
PLAGL1
| Paternal | TG(48:0) | 0.19 | 0.01 | 174 | 0.10 | 0.10 | 248 | 0.14 (0.04, 0.23) | 2.4 × 10−3 |
rs2268445 |
PLAGL1
| Paternal | TG(44:1) | 0.14 | 0.06 | 177 | 0.14 | 0.04 | 218 | 0.14 (0.04, 0.24) | 2.7 × 10−3 |
rs7950932 |
H19
| Maternal | TG(44:1) | 0.09 | 0.21 | 183 | 0.09 | 0.22 | 209 | 0.09 (−0.01, 0.19) | 0.04 |
Associations between the abundance of TG(44:1) at around week 15 of pregnancy and clinically significant parameters
The species most heavily represented in the list of associations with fetal imprinted gene variant alleles by the VIP scores was TG(44:1), a monounsaturated triglyceride. It is also the triglyceride involved in the two most significant associations between fetal imprinted gene alleles and triglycerides in analyses of lipid species where PLS-DA analysis of the Discovery Cohort data led to significant fitted models (Table 4). To investigate whether this isoform was clinically relevant in our population we tested associations between its peak intensities, maternal pre-pregnancy BMI and indices derived from the OGTT (Table 8). Of these in the two sub-cohorts the strongest associations were with fasting glucose concentrations and HOMA IR, both of which were positively related to the abundance of TG(44:1). In turn week 28 fasting glucose concentrations (odds ratio (OR) 4.8 × 1010 (8.5 × 108, 2.7 × 1012), p = 5.7 × 10− 33, n = 1083) and HOMA IR (OR 7.7 (4.8, 12.1), p = 2.7 × 10− 18, n = 1059) were also both positively associated with GDM in the Cambridge Baby Growth Study as a whole. In addition they were both positively associated with baby’s birth weight (fasting glucose concentrations: standardised β = 0.116, p = 3.7 × 10− 6, n = 813; HOMA IR: standardised β = 0.065, p = 0.048, n = 813; both adjusted for gestational age at birth, sex, parity and maternal BMI).
Table 8
Associations between week 15 TG (44:1) peak intensities and biomarkers derived from the week 28 OGTT
Biomarker | Discovery Cohort | Validation Cohort | Meta-Analysis | |||||
|---|---|---|---|---|---|---|---|---|
R | p-value | n | R | p-value | n | R | p-value | |
Pre-pregnancy BMI | −0.10 | 0.21 | 170 | −0.06 | 0.31 | 356 | −0.07 (− 0.16, 0.01) | 0.05 |
Fasting glucose concentration | 0.04 | 0.54 | 195 | 0.11 | 0.02 | 478 | 0.09 (0.01, 0.16) | 9.9 × 10−3 |
Glucose concentration 60 min. post 75 g load | 0.16 | 0.03 | 195 | 0.05 | 0.26 | 478 | 0.09 (−0.01, 0.19) | 0.04 |
Fasting insulin concentration | 0.03 | 0.65 | 189 | 0.10 | 0.03 | 476 | 0.08 (0, 0.16) | 0.02 |
HOMA IR | 0.03 | 0.65 | 189 | 0.12 | 8.8 × 10−3 | 475 | 0.09 (0.01, 0.17) | 0.01 |
HOMA B | 0.03 | 0.72 | 189 | 0.05 | 0.26 | 475 | 0.04 (−0.03, 0.12) | 0.13 |
Anzeige
Discussion
In this detailed investigation of the associations between fetal imprinted gene alleles and the circulating maternal lipid profile around week 15 of pregnancy, we found several significant associations with particular triglyceride isoform peak intensities in the maternal circulation. There was an overrepresentation of maternally-transmitted fetal alleles in the list of associations with fitted models in the PLS-DA analysis. Whilst unexpected this may relate to an influence of triglycerides on fetal growth [13] and the extra influence that maternal genes may have on the resulting offspring birth weight in particular in comparison to paternal genes [28]. In previous studies we observed an influence of fetal imprinted genes on maternal glucose concentrations in pregnancy, although these were much later in pregnancy around week 28 [8, 9]. Results from the current study provide the first evidence for a potential role for fetal imprinted genes in modifying maternal metabolism, in particular circulating levels of certain lipid species, relatively early in pregnancy.
The strongest association was detected with the abundance of maternal circulating TG(44:1), which may include configurations 15:0/15:0/14:1 and/or 15:1/14:0/15:0 [29]. This lipid species was linked to the development of insulin resistance and type 2 diabetes in the Framingham Offspring Study [30]. Importantly, in the current study this isoform was associated with paternally-transmitted fetal rs7950932 (Table 4). This variant is one of the single nucleotide polymorphisms (SNPs) that was used to tag H19, which is generally expressed only from the maternally-transmitted allele [31]. However there was also an association between the maternally-transmitted rs7950932 allele and TG(44:1) (Table 7), possibly resulting from biallelic expression in some tissues at this stage of development (which would be consistent with there also being a significant association with the fetal rs7950932 genotype). In other tissues, however, the alleles may have been expressed only from the paternally-transmitted allele: this interpretation being consistent with the association with the paternally-transmitted allele having a higher regression coefficient (and being more statistically significant) than that with the maternally-transmitted allele. Although when expressed in an imprinted fashion H19 is expressed only from the maternal allele, the rs7950932 locus is located in the proximity of H19’s differentially methylated region [32] which helps regulate paternally-expressed IGF2 as well as H19 expression [33], making the association with the paternally-transmitted allele plausible. Interestingly the abundance of TG(44:1) in maternal serum around week 15 of pregnancy correlated with subsequent (week 28) fasting glucose concentrations and HOMA IR in our population, which in turn were associated with both GDM and offspring birth weight. We have previously found several paternally-transmitted fetal IGF2 variants that were associated with late pregnancy glucose concentrations [8, 9]. Together all these results suggest that the associations between fetal rs7950932 alleles and week 15 maternal TG(44:1) levels may be related to both IGF2 and H19 expression.
The second strongest association in our population was between fetal rs7131362, a downstream variant of the FAM99A gene, and the abundance of maternal week 15 TG(44:1) again. The association was with the maternally-transmitted fetal allele, and with the associations having larger regression coefficients (and greater statistical significance) than those of the equivalent associations with the maternal genotype and the untransmitted maternal alleles, it appears to be directly related to the transmitted fetal allele itself rather than the maternal gene per se. The lack of association with the paternally-transmitted allele is consistent with the fetal effect being modified by imprinting. This variant is in a chromosomal region populated by reciprocally imprinted genes a number of which are maternally-expressed [34]. Although a parent-of-origin effect of this variant on maternal circulating lipid levels has not been evident before, other published studies suggest why such an association may be plausible. Data from the 1000 Genomes project [35] shows a degree of linkage disequilibrium between rs7131362 and rs2334499 (D’ = 0.86), whose maternally-transmitted allele has been associated with risk of type 2 diabetes [36] (with the protective allele in [36] being in linkage disequilibrium with the allele associated with the lower TG(44:1) peak intensity in the present study). In recent years it has become apparent that there is a strong correlation between genetic risk variants for type 2 diabetes and those for GDM [37]. As described above, in our population the abundance of the triglyceride isoform TG(44:1) was associated with factors themselves associated with risk of GDM.
Even the most significant associations found in this study should be considered preliminary in nature. The main limitation of the study is that it was only powered to detect associations with large effect sizes. Nevertheless the main associations in our population appear biologically plausible based on current knowledge in the published literature. The associations need external validation in other cohorts, rather than the internal validation that was used in this study, but they will be useful for meta-analyses once studies in other populations have been completed. Our results suggest that associations with TG(44:1) in pregnancy may be particularly important.
Anzeige
Conclusion
The results of this study suggest that the interaction between the fetal imprinted genotype and maternal metabolism may be detected early in pregnancy through alterations in serum levels of clinically relevant triglycerides in the maternal circulation. This result is remarkable because it suggests that triglycerides, traditionally regarded as merely energy storage molecules, may be involved in the metabolic signalling that controls fetal development. However further validation in more highly powered studies is required to establish this.
Acknowledgements
The authors acknowledge the excellent technical assistance in the laboratory for this project that was provided by Dianne Wingate, Rachel Seear, Katrin Mooslehner and Radka Platte. The authors would like to thank all the families that took part in the Cambridge Baby Growth Study, and acknowledge the crucial role played by the research nurses especially Suzanne Smith, Ann-Marie Wardell and Karen Forbes, staff at the Addenbrooke’s Wellcome Trust Clinical Research Facility, and midwives at the Rosie Maternity Hospital in collecting data for this study.
Funding
The genotyping part of the Cambridge Baby Growth Study was funded by the Evelyn Trust (EW9035322), Diabetes U.K. (11/0004241) and the Wellbeing of Women (the Royal College of Obstetricians and Gynaecologists, U.K.) (RG1644). The lipidomics assays were supported by the Medical Research Council (UD99999906) and Cambridge Lipidomics Biomarker Research Initiative (G0800783). Other core funding has come from the Medical Research Council (G1001995); European Union Framework 5 (QLK4–1999-01422); the Mothercare Charitable Foundation (RG54608); Newlife Foundation for Disabled Children (07/20) and the World Cancer Research Fund International (2004/03). In addition there has been support from National Institute for Health Research Cambridge Biomedical Research Centre. KO is supported by the Medical Research Council (Unit Programme number: MC_UU_12015/2). The various funding bodies took no part in the design of the study, the collection, analysis, and interpretation of the data, or in the writing of the manuscript.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to the possibility of breaking study participant anonymity (due to the presence of SNP genotypes), a condition of the ethical permission granted. However they are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The Cambridge Baby Growth Study was approved by the Local Ethics Committee, Addenbrooke’s Hospital, Cambridge, U.K. (LREC 00/325) and was conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent, including that for anonymised genetic testing, was obtained from the parents, including consent for inclusion of their infants in the study.
Consent for publication
The aim of the study was carefully explained to all of the participants, who provided their written informed consent including that for anonymised genetic testing, for inclusion of their infants in the study and for publication.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.